{"success":true,"data":{"pressRelease":{"id":"150182","rtpr_id":"nGNXbMDWqN-20260922","ticker":"LKFT","exchange":"Euronext Amsterdam","all_tickers":["LKFT"],"title":"Acquisition of Own Shares","author":"Globe Newswire","published_at":"2026-09-22T20:01:00.440Z","article_body":"Mechelen, Belgium; September 22, 2026, 22.01 CET; regulated information\n\nWithin the framework of the repurchase program announced on June 9, 2026,\nLakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (\"Lakefront\") announces\nthat between September 14, 2026 and September 18, 2026 it has repurchased\n108,679 Lakefront shares via a discretionary mandate to an independent\nfinancial intermediary, as follows:\n\n Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) \n 14/09/2026 XAMS 20,177 23.47 473,481.55 23.24 23.62 \n 14/09/2026 CEUX 2,697 23.55 63,515.43 23.50 23.58 \n 14/09/2026 AQEU 984 23.56 23,179.30 23.50 23.60 \n 14/09/2026 TQEX 638 23.55 15,027.20 23.52 23.62 \n 15/09/2026 XAMS 20,575 23.31 479,683.49 23.16 23.74 \n 15/09/2026 CEUX 1,673 23.40 39,150.88 23.20 23.72 \n 15/09/2026 AQEU 659 23.23 15,307.58 23.20 23.30 \n 15/09/2026 TQEX 1,676 23.31 39,068.06 23.24 23.44 \n 16/09/2026 XAMS 20,489 24.14 494,606.51 23.70 24.34 \n 16/09/2026 CEUX 2,809 24.12 67,749.43 23.88 24.36 \n 16/09/2026 AQEU 143 24.28 3,472.04 24.28 24.28 \n 16/09/2026 TQEX 1,273 24.25 30,874.83 23.84 24.38 \n 17/09/2026 XAMS 14,964 24.38 364,808.85 24.20 24.86 \n 17/09/2026 CEUX 1,370 24.27 33,247.30 24.20 24.30 \n 17/09/2026 AQEU 400 24.29 9,717.92 24.28 24.34 \n 17/09/2026 TQEX 730 24.28 17,725.71 24.24 24.34 \n 18/09/2026 XAMS 15,116 25.16 380,250.54 25.06 25.40 \n 18/09/2026 CEUX 1,261 25.09 31,643.03 25.06 25.44 \n 18/09/2026 AQEU 861 25.18 21,681.87 25.06 25.44 \n 18/09/2026 TQEX 184 25.22 4,640.55 25.12 25.40 \n Total 108,679 24.00 2,608,832.08 23.16 25.44 \n\nAs of market close on 18 September 2026, Lakefront holds 1,527,534 of its own\nordinary shares.\n\nAbout Lakefront Biotherapeutics\nLakefront Biotherapeutics is a biotechnology company dedicated to building a\ndifferentiated pipeline of medicines for patients with serious diseases in\nareas of high unmet need. The Company has established a clinical‑stage\nportfolio in immunology and inflammation, anchored by gamgertamig, a potential\nfirst‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune\ndiseases. Backed by deep deal‑making expertise, operational flexibility, and\na strong capital position, Lakefront identifies, acquires, and advances\nhigh‑quality assets with clear potential to deliver meaningful patient\nimpact and long‑term shareholder value. For more information, visit\nhttps://www.lakefrontbio.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=Wx5ZWn97jOqNr9BXW-F8igdIwQWY_CI0bqRQKhNseXjlAhASDhNJzNJGt9-bR2jCm-4FaT032uwuze7E6ZEgMqLdZRoqIhSNcMxHoxM_xY2t8JleI92Cyu_HnECjak7g)\nor X\n(https://www.globenewswire.com/Tracker?data=4YHvJjEZSOGmuvb2yth7lj0iy02KnKcs5ECtsObi8k5EVc0nqPFzSeAX9VUmt8X4_40Ga9YXpEJEFlVOWZJ1SA==).\n\nFor further information, contact Lakefront Biotherapeutics:\nInvestor Relations \nSherri Spear\n+1 412 522 6418\nsherri.spear@lakefrontbio.com\n\nRichie Livingston\n+1 312 636 7072\nrichie.livingston@lakefrontbio.com\n\nForward-looking statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, all of which involve\ncertain risks and uncertainties. These statements are often, but are not\nalways, made through the use of words or phrases such as “believe,”\n“anticipate,” “expect,” “intend,” “plan,” “seek,”\n“upcoming,” “future,” “estimate,” “may,” “will,”\n“could,” “would,” “potential,” “forward,” “goal,”\n“next,” “continue,” “should,” “encouraging,” “aim,”\n“progress,” “remain,” “explore,” and “further,” as well as\nsimilar expressions. These statements include, but are not limited to,\nstatements regarding Lakefront’s plans to repurchase its ordinary shares.\nLakefront cautions the reader that forward-looking statements are based on our\nmanagement’s current expectations and beliefs and are not guarantees of\nfuture performance. Forward-looking statements may involve known and unknown\nrisks, uncertainties and other factors which might cause actual events,\nfinancial condition and liquidity, performance, or achievements, or the\nindustry in which we operate, to be materially different from any historic or\nfuture results, financial conditions, performance or achievements expressed or\nimplied by such forward-looking statements. In addition, even if our results,\nperformance, financial condition and liquidity, and the development of the\nindustry in which Lakefront operates are consistent with such forward-looking\nstatements, they may not be predictive of results or developments in future\nperiods. Such risks include, but are not limited to, those risks and\nuncertainties that can be found in our filings and reports with the Securities\nand Exchange Commission (“SEC”), including in our most recent annual\nreport on Form 20-F filed with the SEC and our subsequent filings and reports\nfiled with the SEC. Given these risks and uncertainties, the reader is advised\nnot to place any undue reliance on such forward-looking statements. In\naddition, even if the result of our operations, financial condition and\nliquidity, or the industry in which we operate, are consistent with such\nforward-looking statements, they may not be predictive of results, performance\nor achievements in future periods. These forward-looking statements speak only\nas of the date of publication of this release. We expressly disclaim any\nobligation to update any such forward-looking statements in this release to\nreflect any change in our expectations or any change in events, conditions or\ncircumstances, unless specifically required by law or regulation.\n\nAttachment\n* 20260918 LakefrontEN RNS Announcement\n(https://ml-eu.globenewswire.com/Resource/Download/424e3385-8761-4cc5-b562-8a5b7e2279fa)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5100317d-9c26-4bbc-9bcc-dd77343f5f96)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbMDWqN-20260922","title":"Acquisition of Own Shares","author":"Globe Newswire","ticker":"LKFT","created":"2026-09-22T20:01:00.440Z","tickers":["LKFT"],"exchange":"Euronext Amsterdam","article_body":"Mechelen, Belgium; September 22, 2026, 22.01 CET; regulated information\n\nWithin the framework of the repurchase program announced on June 9, 2026,\nLakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (\"Lakefront\") announces\nthat between September 14, 2026 and September 18, 2026 it has repurchased\n108,679 Lakefront shares via a discretionary mandate to an independent\nfinancial intermediary, as follows:\n\n Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) \n 14/09/2026 XAMS 20,177 23.47 473,481.55 23.24 23.62 \n 14/09/2026 CEUX 2,697 23.55 63,515.43 23.50 23.58 \n 14/09/2026 AQEU 984 23.56 23,179.30 23.50 23.60 \n 14/09/2026 TQEX 638 23.55 15,027.20 23.52 23.62 \n 15/09/2026 XAMS 20,575 23.31 479,683.49 23.16 23.74 \n 15/09/2026 CEUX 1,673 23.40 39,150.88 23.20 23.72 \n 15/09/2026 AQEU 659 23.23 15,307.58 23.20 23.30 \n 15/09/2026 TQEX 1,676 23.31 39,068.06 23.24 23.44 \n 16/09/2026 XAMS 20,489 24.14 494,606.51 23.70 24.34 \n 16/09/2026 CEUX 2,809 24.12 67,749.43 23.88 24.36 \n 16/09/2026 AQEU 143 24.28 3,472.04 24.28 24.28 \n 16/09/2026 TQEX 1,273 24.25 30,874.83 23.84 24.38 \n 17/09/2026 XAMS 14,964 24.38 364,808.85 24.20 24.86 \n 17/09/2026 CEUX 1,370 24.27 33,247.30 24.20 24.30 \n 17/09/2026 AQEU 400 24.29 9,717.92 24.28 24.34 \n 17/09/2026 TQEX 730 24.28 17,725.71 24.24 24.34 \n 18/09/2026 XAMS 15,116 25.16 380,250.54 25.06 25.40 \n 18/09/2026 CEUX 1,261 25.09 31,643.03 25.06 25.44 \n 18/09/2026 AQEU 861 25.18 21,681.87 25.06 25.44 \n 18/09/2026 TQEX 184 25.22 4,640.55 25.12 25.40 \n Total 108,679 24.00 2,608,832.08 23.16 25.44 \n\nAs of market close on 18 September 2026, Lakefront holds 1,527,534 of its own\nordinary shares.\n\nAbout Lakefront Biotherapeutics\nLakefront Biotherapeutics is a biotechnology company dedicated to building a\ndifferentiated pipeline of medicines for patients with serious diseases in\nareas of high unmet need. The Company has established a clinical‑stage\nportfolio in immunology and inflammation, anchored by gamgertamig, a potential\nfirst‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune\ndiseases. Backed by deep deal‑making expertise, operational flexibility, and\na strong capital position, Lakefront identifies, acquires, and advances\nhigh‑quality assets with clear potential to deliver meaningful patient\nimpact and long‑term shareholder value. For more information, visit\nhttps://www.lakefrontbio.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=Wx5ZWn97jOqNr9BXW-F8igdIwQWY_CI0bqRQKhNseXjlAhASDhNJzNJGt9-bR2jCm-4FaT032uwuze7E6ZEgMqLdZRoqIhSNcMxHoxM_xY2t8JleI92Cyu_HnECjak7g)\nor X\n(https://www.globenewswire.com/Tracker?data=4YHvJjEZSOGmuvb2yth7lj0iy02KnKcs5ECtsObi8k5EVc0nqPFzSeAX9VUmt8X4_40Ga9YXpEJEFlVOWZJ1SA==).\n\nFor further information, contact Lakefront Biotherapeutics:\nInvestor Relations \nSherri Spear\n+1 412 522 6418\nsherri.spear@lakefrontbio.com\n\nRichie Livingston\n+1 312 636 7072\nrichie.livingston@lakefrontbio.com\n\nForward-looking statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, all of which involve\ncertain risks and uncertainties. These statements are often, but are not\nalways, made through the use of words or phrases such as “believe,”\n“anticipate,” “expect,” “intend,” “plan,” “seek,”\n“upcoming,” “future,” “estimate,” “may,” “will,”\n“could,” “would,” “potential,” “forward,” “goal,”\n“next,” “continue,” “should,” “encouraging,” “aim,”\n“progress,” “remain,” “explore,” and “further,” as well as\nsimilar expressions. These statements include, but are not limited to,\nstatements regarding Lakefront’s plans to repurchase its ordinary shares.\nLakefront cautions the reader that forward-looking statements are based on our\nmanagement’s current expectations and beliefs and are not guarantees of\nfuture performance. Forward-looking statements may involve known and unknown\nrisks, uncertainties and other factors which might cause actual events,\nfinancial condition and liquidity, performance, or achievements, or the\nindustry in which we operate, to be materially different from any historic or\nfuture results, financial conditions, performance or achievements expressed or\nimplied by such forward-looking statements. In addition, even if our results,\nperformance, financial condition and liquidity, and the development of the\nindustry in which Lakefront operates are consistent with such forward-looking\nstatements, they may not be predictive of results or developments in future\nperiods. Such risks include, but are not limited to, those risks and\nuncertainties that can be found in our filings and reports with the Securities\nand Exchange Commission (“SEC”), including in our most recent annual\nreport on Form 20-F filed with the SEC and our subsequent filings and reports\nfiled with the SEC. Given these risks and uncertainties, the reader is advised\nnot to place any undue reliance on such forward-looking statements. In\naddition, even if the result of our operations, financial condition and\nliquidity, or the industry in which we operate, are consistent with such\nforward-looking statements, they may not be predictive of results, performance\nor achievements in future periods. These forward-looking statements speak only\nas of the date of publication of this release. We expressly disclaim any\nobligation to update any such forward-looking statements in this release to\nreflect any change in our expectations or any change in events, conditions or\ncircumstances, unless specifically required by law or regulation.\n\nAttachment\n* 20260918 LakefrontEN RNS Announcement\n(https://ml-eu.globenewswire.com/Resource/Download/424e3385-8761-4cc5-b562-8a5b7e2279fa)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5100317d-9c26-4bbc-9bcc-dd77343f5f96)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-22T20:01:00.493376727Z","server_sent_at_ms":1790107260493},"received_at":"2026-09-22T20:01:00.547Z","source_url":null},"analysis":{"id":"138983","press_release_id":"150182","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"buyback","narrative":"Lakefront Biotherapeutics repurchased 108,679 of its own shares between September 14 and September 18, 2026, under the buyback program announced June 9, 2026.\n\nThe purchases were executed via a discretionary mandate to an independent financial intermediary at an average price of €24.00, totaling €2,608,832.08.\n\nAs of the September 18 close, the company holds 1,527,534 of its own ordinary shares, providing modest per-share support for holders.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine weekly buyback progress report under existing program — ongoing per-share accretion signal."},"keyFigures":{"offeringPrice":"€24.00","sharesOffered":108679,"customDimensions":{"total_shares_held":1527534,"avg_price_paid_eur":24,"lowest_price_paid_eur":23.16,"highest_price_paid_eur":25.44}},"namedEntities":{"people":[{"name":"Sherri Spear","role":"Investor Relations"},{"name":"Richie Livingston","role":"Investor Relations"}],"products":["gamgertamig"],"companies":[{"name":"Lakefront Biotherapeutics NV","ticker":"LKFT","relationship":"filer"}],"dollarAmounts":[{"amount":"€2,608,832.08","context":"total spent repurchasing 108,679 shares Sept 14-18, 2026"}]},"materialImpact":{"score":2,"reasoning":"Routine weekly buyback progress disclosure under an existing June 9, 2026 repurchase program — no new authorization or change in scale. Mildly supportive of the stock but boilerplate regulated-information."},"tickerRelevance":{"others":[],"primary":"LKFT"},"globalImportance":12,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine-buyback-weekly-update","issuerAuthored":true}},"event_type":"buyback","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Lakefront Biotherapeutics repurchased 108,679 of its own shares between September 14 and September 18, 2026, under the buyback program announced June 9, 2026.\n\nThe purchases were executed via a discretionary mandate to an independent financial intermediary at an average price of €24.00, totaling €2,608,832.08.\n\nAs of the September 18 close, the company holds 1,527,534 of its own ordinary shares, providing modest per-share support for holders.","key_figures":{"offeringPrice":"€24.00","sharesOffered":108679,"customDimensions":{"total_shares_held":1527534,"avg_price_paid_eur":24,"lowest_price_paid_eur":23.16,"highest_price_paid_eur":25.44}},"named_entities":{"people":[{"name":"Sherri Spear","role":"Investor Relations"},{"name":"Richie Livingston","role":"Investor Relations"}],"products":["gamgertamig"],"companies":[{"name":"Lakefront Biotherapeutics NV","ticker":"LKFT","relationship":"filer"}],"dollarAmounts":[{"amount":"€2,608,832.08","context":"total spent repurchasing 108,679 shares Sept 14-18, 2026"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-22T20:01:05.304Z","global_importance":12,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine-buyback-weekly-update","issuerAuthored":true}},"durationMs":4741,"modelName":"glm-5.3-flashx"}}